• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 4. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrazines

Recent Advances in the Study of 2-Isobutyl-3,5,6-trimethylpyrazine (CAS: 46187-37-5) in Chemical Biology and Pharmaceutical Research

2-Isobutyl-3,5,6-trimethylpyrazine (CAS: 46187-37-5) is a pyrazine derivative that has garnered significant attention in the fields of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a flavoring agent, its pharmacological activities, and its potential use in drug development. This research brief synthesizes the latest findings on this compound, providing insights into its molecular mechanisms, bioactivity, and industrial applications.

One of the most notable aspects of 2-Isobutyl-3,5,6-trimethylpyrazine is its presence in various natural sources, including certain plants and fermented foods. Its distinct aroma profile has made it a valuable component in the food and fragrance industries. However, recent research has shifted focus toward its biological activities, such as its antioxidant, anti-inflammatory, and antimicrobial properties. Studies have demonstrated that this compound can modulate key signaling pathways, suggesting its potential as a lead compound for developing novel therapeutics.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers investigated the compound's interaction with cellular receptors, particularly those involved in inflammation and oxidative stress. The study employed molecular docking simulations and in vitro assays to elucidate its binding affinity and mechanistic effects. Results indicated that 2-Isobutyl-3,5,6-trimethylpyrazine exhibits a high affinity for certain inflammatory markers, positioning it as a promising candidate for further drug development.

Another significant advancement was reported in a 2024 ACS Chemical Biology article, which explored the compound's potential in cancer therapy. The research team synthesized analogs of 2-Isobutyl-3,5,6-trimethylpyrazine and evaluated their cytotoxicity against various cancer cell lines. Preliminary findings revealed that certain derivatives displayed selective toxicity toward cancer cells while sparing normal cells, highlighting the compound's potential as a scaffold for designing targeted anticancer agents.

Beyond its pharmacological applications, 2-Isobutyl-3,5,6-trimethylpyrazine has also been studied for its role in metabolic engineering. A recent Nature Biotechnology publication detailed the use of synthetic biology techniques to enhance the production of this compound in microbial hosts. By optimizing biosynthetic pathways, researchers achieved higher yields, paving the way for scalable and cost-effective production methods. This breakthrough has significant implications for both industrial and pharmaceutical applications.

In conclusion, the latest research on 2-Isobutyl-3,5,6-trimethylpyrazine (CAS: 46187-37-5) underscores its multifaceted potential in chemical biology and pharmaceutical sciences. From its therapeutic properties to its industrial relevance, this compound continues to inspire innovative research. Future studies should focus on elucidating its pharmacokinetics, toxicity profiles, and clinical applicability to fully realize its promise in drug development and beyond.

• 70303-42-3(Pyrazine, 3,5-dimethyl-2-(2-methylpropyl)-)
• 117783-42-3(Pyrazine,5-ethyl-3-methyl-2-(2-methylpropyl)-)
• 117783-43-4(Pyrazine,5-ethyl-2-methyl-3-(2-methylpropyl)-)
• 920018-22-0(Phenazine, 1,2,3,4,6,7,8,9-octahydro-2,7-dimethyl-)
• 18433-98-2(Pyrazine,2,5-dimethyl-3-(3-methylbutyl)-)
• 38888-81-2(3,5-Dimethyl-2-isobutylpyrazine)
• 54410-83-2(5-Isobutyl-2,3-dimethylpyrazine)
• 111150-30-2(Pyrazine,3,5-dimethyl-2-(3-methylbutyl)-)
• 13925-06-9(2-Isobutyl-3-methylpyrazine)
• 72668-36-1(Pyrazine,2,5-dimethyl-3-(2-methylbutyl)-)